<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">Von Willebrand</z:e> factor (vWF) plays an important role in the coagulation system </plain></SENT>
<SENT sid="1" pm="."><plain>It affects platelet aggregation in the place of vessel endothelium damage </plain></SENT>
<SENT sid="2" pm="."><plain>The importance of vWF in cerebrovascular disease is not clear </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this presentation was to evaluate the vWF level in the plasma and cerebrospinal fluid of patients after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> including cases with <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>We investigated 66 patients (38 persons graded I-III H&amp;H and 28 persons graded IV H&amp;H) </plain></SENT>
<SENT sid="5" pm="."><plain>The control group consists of 8 subjects </plain></SENT>
<SENT sid="6" pm="."><plain>VWF was measured by ELISA method using standard kit Asserachrom (Boehringer) </plain></SENT>
<SENT sid="7" pm="."><plain>The vWF level in the plasma reached 288.81 +/- 99.66% (in the control group, 98.84 +/- 14.53%) without significant differences regarding clinical condition of patients </plain></SENT>
<SENT sid="8" pm="."><plain>In the cerebrospinal fluid the vWF level was significantly different in I-III H&amp;H patients and in IV H&amp;H patients (1.21 +/- 0.52% and 9.18 +/- 7.58%, respectively, p &lt; 0.001) and in the control group (0.13 +/- 0.33%) </plain></SENT>
<SENT sid="9" pm="."><plain>Our data indicate that there is correlation (Pearson, p &lt; 0.01) between the level of vWF and neurological condition (GCS) of patients </plain></SENT>
<SENT sid="10" pm="."><plain>There is also correlation (p &lt; 0.01) between the level of VWF and the presence of clinical disorders (<z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, delayed neurological deficit (DIND) and cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath>) </plain></SENT>
<SENT sid="11" pm="."><plain>Based on multivariate analysis, we confirmed that vWF is an independent prognostic factor of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> (p &lt; 0.01) and ischemic complications (p &lt; 0.02) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: vWF is elevated in the plasma of patients after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> in early stage of the disease </plain></SENT>
<SENT sid="13" pm="."><plain>VWF is present in the cerebrospinal fluid of patients with SAH and its level is higher in patients with poor neurological condition </plain></SENT>
<SENT sid="14" pm="."><plain>The VWF elevation in csf is correlated with clinical condition of patients and also the presence of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> </plain></SENT>
<SENT sid="15" pm="."><plain>VWF can be used as an independent prognostic factor of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and ischemic complications </plain></SENT>
</text></document>